# OnCo record lymphoma-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/lymphoma-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "lymphoma-roadmap" ;
  schema:name "Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting"@en ;
  schema:alternateName "Lymphoma history"@en, "Lymphoma evidence roadmap"@en, "Hodgkin and non-Hodgkin lymphoma roadmap"@en, "How lymphoma treatment was worked out"@en ;
  schema:description "Lymphoma was the first cancer shown to be caused by a virus, the first common cancer sorted into subtypes by reading which genes were switched on, and the first in which a patient's own immune cells were reprogrammed to cure them. This roadmap follows the evidence from 1958 to the trials reading out in 2032."@en ;
  schema:url <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq>, <https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq>, <https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-haematological-malignancies>, <https://b-s-h.org.uk/guidelines/>, <https://clinicaltrials.gov/study/NCT04685616>, <https://clinicaltrials.gov/study/NCT06337318> ;
  onco:related <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/roadmaps/chemotherapy-roadmap/>, <https://onco.cc/roadmaps/radiation-roadmap/>, <https://onco.cc/ideas/idea-chemo-free-hodgkin/>, <https://onco.cc/ideas/idea-cd30-car-t-hodgkin/>, <https://onco.cc/ideas/idea-prev-ebv-vaccine/>, <https://onco.cc/ideas/lymphoma-ev-genetic-subtype-directed-first-line/>, <https://onco.cc/ideas/lymphoma-ev-ctdna-instead-of-the-interim-scan/>, <https://onco.cc/ideas/lymphoma-ev-radiotherapy-free-early-hodgkin/>, <https://onco.cc/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/>, <https://onco.cc/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/>, <https://onco.cc/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/>, <https://onco.cc/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/>, <https://onco.cc/ideas/lymphoma-ev-late-effects-of-the-treatments-given-now/> ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/malt-lymphoma/>, <https://onco.cc/cancers/primary-cns-lymphoma/>, <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/>, <https://onco.cc/cancers/waldenstrom/> ;
  onco:sections <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/radiation/>, <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/prevention/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/terms/ngs/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/bcl6/>, <https://onco.cc/pathways/myc/>, <https://onco.cc/targets/myd88/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/btk/>, <https://onco.cc/targets/notch1/>, <https://onco.cc/targets/notch2/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/ccnd1/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/asparaginase/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/johnson-johnson/> ;
  onco:institutions <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/cruk/>, <https://onco.cc/institutions/nice/>, <https://onco.cc/institutions/esmo/> ;
  onco:pathways <https://onco.cc/pathways/bcr-signalling/>, <https://onco.cc/pathways/jak-stat/>, <https://onco.cc/pathways/apoptosis-bcl2/> ;
  onco:terms <https://onco.cc/terms/cell-of-origin/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/flipi/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/double-hit-lymphoma/>, <https://onco.cc/terms/autologous-transplant/>, <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/terms/lymphoma-tx-pod24/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/> ;
  onco:trials <https://onco.cc/trials/polarix/>, <https://onco.cc/trials/echelon-1/>, <https://onco.cc/trials/echelon-2/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/trials/zuma-1/>, <https://onco.cc/trials/zuma-5/>, <https://onco.cc/trials/zuma-7/>, <https://onco.cc/trials/transform/>, <https://onco.cc/trials/belinda/>, <https://onco.cc/trials/epcore-nhl-1/>, <https://onco.cc/trials/triangle/>, <https://onco.cc/trials/gallium/>, <https://onco.cc/trials/relevance/>, <https://onco.cc/trials/alcanza/>, <https://onco.cc/trials/ielsg32/>, <https://onco.cc/trials/ielsg43/>, <https://onco.cc/trials/starglo/>, <https://onco.cc/trials/shine/>, <https://onco.cc/trials/enrich/>, <https://onco.cc/trials/lyma/>, <https://onco.cc/trials/flyer/>, <https://onco.cc/trials/calgb-50303/>, <https://onco.cc/trials/goya/>, <https://onco.cc/trials/remarc/>, <https://onco.cc/trials/polargo/>, <https://onco.cc/trials/juliet/>, <https://onco.cc/trials/transcend-nhl-001/>, <https://onco.cc/trials/prima-follicular/>, <https://onco.cc/trials/ielsg-19/>, <https://onco.cc/trials/trog-99-03/>, <https://onco.cc/trials/elara/>, <https://onco.cc/trials/rosewood/>, <https://onco.cc/trials/hd10/>, <https://onco.cc/trials/hd16/>, <https://onco.cc/trials/hd18/>, <https://onco.cc/trials/ahl2011/>, <https://onco.cc/trials/eortc-h10/>, <https://onco.cc/trials/jcog9801/>, <https://onco.cc/trials/smile-enktl/>, <https://onco.cc/trials/radar-hodgkin/>, <https://onco.cc/trials/polar-bear/>, <https://onco.cc/trials/arched/>, <https://onco.cc/trials/prima-cns/>, <https://onco.cc/trials/fortplus/>, <https://onco.cc/trials/mosun-lbt-fl/>, <https://onco.cc/trials/mosun-len-mzl/> ;
  onco:people <https://onco.cc/people/louis-staudt/>, <https://onco.cc/people/ash-alizadeh/>, <https://onco.cc/people/gilles-salles/>, <https://onco.cc/people/laurie-sehn/>, <https://onco.cc/people/martin-dreyling/>, <https://onco.cc/people/michael-wang/>, <https://onco.cc/people/peter-borchmann/>, <https://onco.cc/people/andreas-engert/>, <https://onco.cc/people/catherine-thieblemont/>, <https://onco.cc/people/franck-morschhauser/>, <https://onco.cc/people/andres-ferreri/>, <https://onco.cc/people/caron-jacobson/>, <https://onco.cc/people/stephen-schuster/>, <https://onco.cc/people/jason-westin/>, <https://onco.cc/people/michael-dickinson/>, <https://onco.cc/people/john-leonard/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/>, <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-global-access/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-negative-results/>, <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-alizadeh-nature/>, <https://onco.cc/key-papers/paper-rosenwald-molecular-profiling-dlbcl-nejm-2002/>, <https://onco.cc/key-papers/paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004/>, <https://onco.cc/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/>, <https://onco.cc/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/>, <https://onco.cc/key-papers/paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020/>, <https://onco.cc/key-papers/paper-cheson-j-clin-oncol/>, <https://onco.cc/key-papers/paper-casulo-pod24-follicular-lymphoma-jco-2015/>, <https://onco.cc/key-papers/paper-scherer-ctdna-lymphoma-subtypes-genome-evolution-sci-transl-med-2016/>, <https://onco.cc/key-papers/paper-kurtz-j-clin-oncol/>, <https://onco.cc/key-papers/paper-burkitt-sarcoma-involving-jaws-african-children-br-j-surg-1958/>, <https://onco.cc/key-papers/paper-epstein-virus-particles-burkitt-lymphoblasts-lancet-1964/>, <https://onco.cc/key-papers/paper-poiesz-htlv-retrovirus-cutaneous-t-cell-lymphoma-pnas-1980/>, <https://onco.cc/key-papers/paper-hinuma-adult-t-cell-leukaemia-antigen-pnas-1981/>, <https://onco.cc/key-papers/paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015/>, <https://onco.cc/key-papers/paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015/>, <https://onco.cc/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/>, <https://onco.cc/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/>, <https://onco.cc/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/>, <https://onco.cc/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/>, <https://onco.cc/key-papers/paper-prima-final-rituximab-maintenance-follicular-jco-2019/>, <https://onco.cc/key-papers/paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025/>, <https://onco.cc/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/> .